Speaker

Adam L Boxer is the endowed professor in memory and aging in the Department of Neurology at the University of California, San Francisco (UCSF). He received his MD and PhD degrees from the New York University Medical Center medical scientist training programme and completed a residency in neurology at Stanford University and a neurobehaviour fellowship at UCSF. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) clinical trials programme at the UCSF Memory and Aging Center. Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He is also the principal investigator of the Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) consortium, a collaborative project funded by the National Institutes of Health to create a multicentre North American research network. Professor Boxer leads the 4 Repeat Tauopathy Neuroimaging Initiative, a multicentre, longitudinal tau PET and biomarker study focused on progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). He is co-principal investigator of the ARTFL-Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Longitudinal Frontotemporal Lobar Degeneration project, a new research network focused on preparing for clinical trials on frontotemporal lobar degeneration (FTLD). He has been the principal investigator for various multicentre, randomised, placebo-controlled clinical trials in FTLD spectrum disorders. He co-chairs the FTLD Treatment Study Group and the PSP Research Roundtable, which are collaborative groups of academia and industry working to quicken the development of new therapies for FTLD, CBD, and PSP.

« Go Back